Frontier Capital Management CO LLC Alkermes Plc. Transaction History

Frontier Capital Management CO LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$21.47 - $37.33 $1.96 Million - $3.42 Million	-91,507 Closed	0 $0
Q1 2019 May 07, 2019	BUY	$28.4 - $36.49 $2.6 Million - $3.34 Million	91,507 New	91,507 $3.34 Million
Q4 2018 Jan 25, 2019	SELL	$27.94 - $44.61 $19.8 Million - $31.6 Million	-707,498 Closed	0 $0
Q3 2018 Oct 30, 2018	BUY	$38.6 - $46.12 $917,715 - $1.1 Million	23,775 Added 3.48%	707,498 $30 Million
Q2 2018 Aug 03, 2018	SELL	$40.56 - $51.36 $1.51 Million - $1.91 Million	-37,143 Reduced 5.15%	683,723 $28.1 Million
Q1 2018 Apr 30, 2018	BUY	$53.61 - $67.26 $2.67 Million - $3.35 Million	49,818 Added 7.42%	720,866 $41.8 Million
Q4 2017 Jan 18, 2018	SELL	$47.69 - $55.39 $5.52 Million - $6.41 Million	-115,695 Reduced 14.71%	671,048 $36.7 Million
Q3 2017 Oct 31, 2017	BUY	$49.16 - $54.45 $38.7 Million - $42.8 Million	786,743	786,743 $40 Million

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Frontier Capital Management CO LLC with notifications on news.